vs
Forafric Global PLC（AFRI）与BIOCRYST PHARMACEUTICALS INC（BCRX）财务数据对比。点击上方公司名可切换其他公司
Forafric Global PLC的季度营收约是BIOCRYST PHARMACEUTICALS INC的1.0倍（$159.7M vs $156.4M）
Forafric Global PLC是一家聚焦非洲市场的农业综合企业，业务覆盖农产品生产、加工、分销全价值链，主营谷物、植物油等主食产品，核心市场为北非和西非地区，服务多领域客户，助力区域粮食安全保障。
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
AFRI vs BCRX — 直观对比
营收规模更大
AFRI
是对方的1.0倍
$156.4M
损益表 — Q2 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $159.7M | $156.4M |
| 净利润 | $-12.0M | — |
| 毛利率 | 10.7% | — |
| 营业利润率 | -2.5% | 13.6% |
| 净利率 | -7.5% | — |
| 营收同比 | — | 7.5% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | — | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AFRIBCRX
| Q1 26 | — | $156.4M | ||
| Q4 25 | — | $406.6M | ||
| Q3 25 | — | $159.4M | ||
| Q2 25 | $159.7M | $163.4M | ||
| Q1 25 | — | $145.5M | ||
| Q4 24 | — | $131.5M | ||
| Q3 24 | — | $117.1M | ||
| Q2 24 | $145.6M | $109.3M |
净利润AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $245.8M | ||
| Q3 25 | — | $12.9M | ||
| Q2 25 | $-12.0M | $5.1M | ||
| Q1 25 | — | $32.0K | ||
| Q4 24 | — | $-26.8M | ||
| Q3 24 | — | $-14.0M | ||
| Q2 24 | $-8.6M | $-12.7M |
毛利率AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 97.7% | ||
| Q3 25 | — | 98.6% | ||
| Q2 25 | 10.7% | 98.3% | ||
| Q1 25 | — | 96.9% | ||
| Q4 24 | — | 95.4% | ||
| Q3 24 | — | 97.3% | ||
| Q2 24 | 9.4% | 98.4% |
营业利润率AFRIBCRX
| Q1 26 | — | 13.6% | ||
| Q4 25 | — | 64.0% | ||
| Q3 25 | — | 18.6% | ||
| Q2 25 | -2.5% | 18.2% | ||
| Q1 25 | — | 14.6% | ||
| Q4 24 | — | -3.4% | ||
| Q3 24 | — | 6.6% | ||
| Q2 24 | -0.9% | 8.0% |
净利率AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 60.5% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | -7.5% | 3.1% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | -20.4% | ||
| Q3 24 | — | -12.0% | ||
| Q2 24 | -5.9% | -11.6% |
每股收益（稀释后）AFRIBCRX
| Q1 26 | — | $0.00 | ||
| Q4 25 | — | $1.13 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $0.02 | ||
| Q1 25 | — | $0.00 | ||
| Q4 24 | — | $-0.13 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.2M | $259.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.3M | — |
| 总资产 | $246.1M | $465.1M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资AFRIBCRX
| Q1 26 | — | $259.0M | ||
| Q4 25 | — | $274.7M | ||
| Q3 25 | — | $212.9M | ||
| Q2 25 | $12.2M | $260.0M | ||
| Q1 25 | — | $295.1M | ||
| Q4 24 | — | $320.9M | ||
| Q3 24 | — | $96.8M | ||
| Q2 24 | $16.4M | $78.4M |
总债务AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $18.4M | — |
股东权益AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $-119.2M | ||
| Q3 25 | — | $-387.9M | ||
| Q2 25 | $5.3M | $-421.6M | ||
| Q1 25 | — | $-451.9M | ||
| Q4 24 | — | $-475.9M | ||
| Q3 24 | — | $-468.6M | ||
| Q2 24 | $16.3M | $-475.6M |
总资产AFRIBCRX
| Q1 26 | — | $465.1M | ||
| Q4 25 | — | $514.2M | ||
| Q3 25 | — | $446.4M | ||
| Q2 25 | $246.1M | $457.2M | ||
| Q1 25 | — | $480.0M | ||
| Q4 24 | — | $490.4M | ||
| Q3 24 | — | $491.3M | ||
| Q2 24 | $287.1M | $472.4M |
负债/权益比AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.13× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $706.0K | — |
| 自由现金流经营现金流 - 资本支出 | $146.0K | — |
| 自由现金流率自由现金流/营收 | 0.1% | — |
| 资本支出强度资本支出/营收 | 0.4% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $292.0M | ||
| Q3 25 | — | $41.6M | ||
| Q2 25 | $706.0K | $41.3M | ||
| Q1 25 | — | $-27.5M | ||
| Q4 24 | — | $-5.2M | ||
| Q3 24 | — | $8.2M | ||
| Q2 24 | $10.5M | $-1.4M |
自由现金流AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | $291.2M | ||
| Q3 25 | — | $40.3M | ||
| Q2 25 | $146.0K | $41.1M | ||
| Q1 25 | — | $-27.7M | ||
| Q4 24 | — | $-5.9M | ||
| Q3 24 | — | $8.2M | ||
| Q2 24 | $6.4M | $-1.5M |
自由现金流率AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 71.6% | ||
| Q3 25 | — | 25.3% | ||
| Q2 25 | 0.1% | 25.2% | ||
| Q1 25 | — | -19.0% | ||
| Q4 24 | — | -4.5% | ||
| Q3 24 | — | 7.0% | ||
| Q2 24 | 4.4% | -1.4% |
资本支出强度AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.8% | ||
| Q2 25 | 0.4% | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 0.1% | ||
| Q2 24 | 2.8% | 0.1% |
现金转化率AFRIBCRX
| Q1 26 | — | — | ||
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 8.12× | ||
| Q1 25 | — | -859.91× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AFRI
| Sales to external customers, Total | $159.7M | 100% |
| Couscous & Pasta | $934.0K | 1% |
| Soft Wheat | $393.0K | 0% |
BCRX
| ORLADEYO | $148.3M | 95% |
| Other revenues | $5.0M | 3% |
| License revenue | $3.0M | 2% |
